<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01372839</url>
  </required_header>
  <id_info>
    <org_study_id>xj050511</org_study_id>
    <nct_id>NCT01372839</nct_id>
  </id_info>
  <brief_title>Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome</brief_title>
  <acronym>PCI</acronym>
  <official_title>The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare with regular regimen, the aim of this study is to testify whether having more statin
      during PCI will benefit in Chinese population, and to find out optimal dose of the drug for
      patient after PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to find out whether patients undergoing PCI can benefit from intensive
      atorvastatin treatment compared with routine treatment on chinese population.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day major adverse cardiovascular events (combined endpoints of cardiac death, myocardial infarction, and target vessel revascularization ) after PCI</measure>
    <time_frame>30-day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-procedural change of inflammatory biomarkers (hs-CRP)</measure>
    <time_frame>24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity of CIN</measure>
    <time_frame>48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elevation of ALT, AST and CK</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients who experience at least once AST&gt;3UNL，ALT&gt;3UNL or CK&gt;5UNL after initiation of study treatment. Proportion of patients who experience at least once AST, ALT, or CK&gt;UNL after initiation of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients who take reduced dose of atorvastatin, withdraw study treatment, or withdraw study due to adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined endpoint of MACEs, cardiac hospitalization and cerebrovascular events</measure>
    <time_frame>6 months</time_frame>
    <description>Combined endpoint of death, cardiac death, myocardial infarction, heart failure, cardiac hospitalization, revascularization, and cerebrovascular events within 6 months after PCI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum adiponectin concentration</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Unstable Angina</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>statin dose should not be higher than that described in exclusion criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>Usual care, but statin dose should not be higher than that described in exclusion criteria</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-85 years old

          -  Patients with clinical diagnosis of ACS

          -  Evidence of a personally signed and dated informed consent document

        Exclusion Criteria:

          -  Taking or, needing to take atorvastatin over than 20mg/d or any other equivalent
             statin in the next 6 months, or needing to take fibrates simultaneously according to
             investigators' judgment.

          -  LDL-C &lt; 1.8mmol/L in patients without statin therapy in 1 months

          -  Endstage congestive heart failure, or LVEF &lt; 30%

          -  Active hepatic disease or hepatic dysfunction, or AST/ALT &gt; 1.5UNL

          -  Myopathy or increased creatine kinase (CK&gt;2 UNL)

          -  Severe renal dysfunction(Scr &gt; 3 mg/dl or 264μmol/L)

          -  Allergic or experienced serious adverse reaction to HMG-CoA reductase, or ineligible
             to take statin as investigator's judgment

          -  Severe aortic valve stenosis or severe mitral stenosis, Obstructive hypertrophic
             cardiomyopathy, pericardial diseases

          -  Pregnancy, lactation, or child bearing potential women without any effective
             contraception

          -  Accompanied with malignant disease or other disease, which cause life expectancy &lt; 6
             months

          -  Participating in other interventional clinical trails using drugs or devices

          -  Patients with any condition which, in the investigator's judgment, might increase the
             risk to the subject for any adverse event or abnormal laboratory finding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Huo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Division of Cardiology, Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling Tao, M.D Ph.D</last_name>
    <phone>+86-15002955798</phone>
    <email>lingtao2006@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Tao, M.D Ph.D</last_name>
      <phone>+86-15002955798</phone>
      <email>lingtao2006@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ling Tao, M.D Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2011</study_first_submitted>
  <study_first_submitted_qc>June 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2011</study_first_posted>
  <last_update_submitted>June 11, 2011</last_update_submitted>
  <last_update_submitted_qc>June 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ling Tao</name_title>
    <organization>Department of Cardiology of Xijing Hospital; Fourth Military Medical University</organization>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Unstable Angina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

